Close Menu

NEW YORK – Previously using a breath-based method to develop its diagnostic tests, Canary Health Technologies is expanding its reach as a result of the COVID-19 pandemic to other sample types, using the same biosensor technology.

It has submitted its saliva-based Pelican CV-19 test and Pelican CV-19 analyzer to the US Food and Drug Administration for Emergency Use Authorization as an over-the-counter at-home test and is preparing to supply the test commercially when and if the authorization is granted. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.